Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2018 08:10 ET | Source: Novartis Pharma AG

Novartis erhält positive CHMP-Stellungnahme für Kymriah® zur Behandlung zweier aggressiver Blutkrebsarten - ein wichtiger medizinischer Fortschritt für Patientinnen und Patienten in Europa

Erste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei...
June 29, 2018 08:10 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe

First CHMP opinion for a CAR-T cell therapy in two distinct indications - DLBCL in adults and B-cell ALL in children Marketing Authorization Application (MAA) based on landmark global CAR-T...
June 29, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis annonce son intention de solliciter l'approbation des actionnaires pour la scission à 100% d'Alcon, sa division de produits ophtalmologiques, et initie un rachat d'actions à hauteur d'USD ...

L'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique ...
June 29, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis gibt Absicht bekannt, die Genehmigung der Aktionäre für einen 100%igen Spin-off des Geschäfts mit ophthalmologischen Produkten von Alcon einzuholen und leitet gleichzeitig einen Aktienrück...

Die strategische Überprüfung von Alcon ergibt, dass ein 100%iger Spin-off im besten Interesse der Aktionäre ist und im Einklang mit der Strategie von Novartis steht, sich als Arzneimittelunternehmen...
June 29, 2018 01:00 ET | Source: Novartis Pharma AG

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn

Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create...
June 28, 2018 16:30 ET | Source: Novartis Pharma AG

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine

Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be...
June 27, 2018 16:30 ET | Source: Novartis Pharma AG

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

Study reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to...
June 26, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also...
June 18, 2018 01:15 ET | Source: Novartis Pharma AG

Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress...
June 16, 2018 05:30 ET | Source: Novartis Pharma AG

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] Patients had a 65% chance of being...